1. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug
reactions in hospitalized patients: a meta-analysis of prospective
studies. JAMA. 1998;279:1200–5.
2. FDA (2018). Preventable Adverse Drug Reactions: A Focus on
Drug Interactions. https://www.fda.gov/drugs/drug-interactions-
labeli ng/p reven table-a dvers e-d rug-r eacti ons-f ocus-d rug-i ntera ctio
ns. Accessed 22 August 2022.
3. Huybrechts KF, Desai RJ, Park M, Gagne JJ, Najafzadeh M,
Avorn J. The potential return on public investment in detecting
adverse drug effects. Med Care. 2017;55:545–51.
4. Downing NS, Shah ND, Aminawung JA, Pease AM, Zeitoun JD,
Krumholz HM, et al. Postmarket safety events among novel therapeutics approved by the US food and drug administration between
2001 and 2010. JAMA. 2017;317:1854–63.
5. Rogers AS. Adverse drug events: identification and attribution.
Drug Intell Clin Pharm. 1987;21:915–20.
6. Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the
public version of the FDA adverse event reporting system. Int J
Med Sci. 2013;10:796–803.
7. Chasioti D, Yao X, Zhang P, Lerner S, Quinney SK, Ning X,
et al. Mining directional drug interaction effects on myopathy
using the FAERS database. IEEE J Biomed Health Inform.
2019;23:2156–63.
8. Sarangdhar M, Tabar S, Schmidt C, Kushwaha A, Shah K, Dahlquist JE, et al. Data mining differential clinical outcomes associated with drug regimens using adverse event reporting data. Nat
Biotechnol. 2016;34:697–700.
9. Gibbons RD, Amatya AK, Brown CH, Hur K, Marcus SM, Bhaumik DK, et al. Post-approval drug safety surveillance. Annu Rev
Public Health. 2010;31:419–37.
10. Kaneko S, Nagashima T. Drug repositioning and target finding
based on clinical evidence. Biol Pharm Bull. 2020;43:362–5.
H. Yamamoto et al.
11. Hazell L, Shakir SA. Under-reporting of adverse drug reactions.
A systematic review. Drug Saf. 2006;29:385–96.
12. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA,
et al. A method for estimating the probability of adverse drug
reactions. Clin Pharmacol Ther. 1981;30:239–45.
13. Gallagher RM, Kirkham JJ, Mason JR, Bird KA, Williamson
PR, Nunn AJ, et al. Development and inter-rater reliability of the
Liverpool adverse drug reaction causality assessment tool. PLoS
ONE. 2011;6: e28096.
14. Harpaz R, Vilar S, Dumouchel W, Salmasian H, Haerian K, Shah
NH, et al. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J Am
Med Inform Assoc. 2013;20:413–9.
15. Li Y, Ryan PB, Wei Y, Friedman CA. Method to combine signals
from spontaneous reporting systems and observational healthcare
data to detect adverse drug reactions. Drug Saf. 2015;38:895–908.
16. Wang L, Rastegar-Mojarad M, Ji Z, Liu S, Liu K, Moon S, et al.
Detecting pharmacovigilance signals combining electronic medical records with spontaneous reports: a case study of conventional
disease-modifying antirheumatic drugs for rheumatoid arthritis.
Front Pharmacol. 2018;9:875.
17. West SL, Johnson W, Visscher W, Kluckman M, Qin Y, Larsen
A. The challenges of linking health insurer claims with electronic
medical records. Health Inform J. 2014;20:22–34.
18. Lai EC, Pratt N, Hsieh CY, Lin SJ, Pottegård A, Roughead EE,
et al. Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies. Eur J Epidemiol. 2017;32:567–82.
19. Hallas J, Wang SV, Gagne JJ, Schneeweiss S, Pratt N, Pottegård
A. Hypothesis-free screening of large administrative databases
for unsuspected drug-outcome associations. Eur J Epidemiol.
2018;33:545–55.
20. Takada M, Fujimoto M, Hosomi K. Association between benzodiazepine use and dementia: data mining of different medical
databases. Int J Med Sci. 2016;13:825–34.
21. Adimadhyam S, Schumock GT, Calip GS, Smith Marsh DE,
Layden BT, Lee TA. Increased risk of mycotic infections associated with sodium-glucose co-transporter 2 inhibitors: a prescription sequence symmetry analysis. Br J Clin Pharmacol.
2019;85:160–8.
22. Li XX, Cheng YC, Zhai SD, Yao P, Zhan SY, Shi LW. Risk of
liver injury associated with intravenous lipid emulsions: a prescription sequence symmetry analysis. Front Pharmacol. 2021;12:
589091.
23. Wahab IA, Pratt NL, Wiese MD, Kalisch LM, Roughead EE.
The validity of sequence symmetry analysis (SSA) for adverse
drug reaction signal detection. Pharmacoepidemiol Drug Saf.
2013;22:496–502.
24. Zhan C, Roughead E, Liu L, Pratt N, Li J. A data-driven method
to detect adverse drug events from prescription data. J Biomed
Inform. 2018;85:10–20.
25. Hoang T, Liu J, Roughead E, Pratt N, Li J. Supervised signal
detection for adverse drug reactions in medication dispensing
data. Comput Methods Programs Biomed. 2018;161:25–38.
26. Zhan C, Roughead E, Liu L, Pratt N, Li J. Detecting potential
signals of adverse drug events from prescription data. Artif Intell
Med. 2020;104: 101839.
27. Banda JM, Evans L, Vanguri RS, Tatonetti NP, Ryan PB, Shah
NH. A curated and standardized adverse drug event resource to
accelerate drug safety research. Sci Data. 2016;3: 160026.
28. Coloma PM, Avillach P, Salvo F, Schuemie MJ, Ferrajolo C, Pariente A, et al. A reference standard for evaluation of methods for
drug safety signal detection using electronic healthcare record
databases. Drug Saf. 2013;36:13–23.
389
Early Detection for ADR Signals by Data-Mining
29. Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S,
Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Saf. 2013;36(Suppl 1):S33-47.
30. Harpaz R, Odgers D, Gaskin G, DuMouchel W, Winnenburg
R, Bodenreider O, et al. A time-indexed reference standard of
adverse drug reactions. Sci Data. 2014;1: 140043.
31. Ietswaart R, Arat S, Chen AX, Farahmand S, Kim B, DuMouchel
W, et al. Machine learning guided association of adverse drug
reactions with in vitro target-based pharmacology. EBioMedicine.
2020;57: 102837.
32. Agrawal R, Srikant R. Fast Algorithms for Mining Association
Rules. In J. B. Bocca, M. Jarke, and C. Zaniolo, editors, Proc. 20th
Int. Conf. Very Large Data Bases, VLDB, 1994; pages 487–499.
33. Harpaz R, Chase HS, Friedman C. Mining multi-item drug
adverse effect associations in spontaneous reporting systems.
BMC Bioinformatics. 2010;11(Suppl 9):S7.
34. Fujiwara M, Kawasaki Y, Yamada H. A pharmacovigilance
approach for post-marketing in Japan using the Japanese adverse
drug event report (JADER) database and association analysis.
PLoS ONE. 2016;11: e0154425.
35. Yildirim P. Association patterns in open data to explore ciprofloxacin adverse events. Appl Clin Inform. 2015;6:728–47.
36. Jorge AM, Azevedo PJ. An Experiment with association rules and
classification: post-bagging and conviction. Proceedings of the
8th international conference on Discovery Science. 2005; Pages
137–149.
37. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin
Epidemiol. 2005;58:323–37.
38. Idema DL, Wang Y, Biehl M, Horvatovich PL, Hak E. Effect
estimate comparison between the prescription sequence symmetry
39. 40. 41. 42. 43. 44. 45. 46. analysis (PSSA) and parallel group study designs: a systematic
review. PLoS ONE. 2018;13: e0208389.
Morris EJ, Hollmann J, Hofer AK, Bhagwandass H, Oueini R,
Adkins LE, et al. Evaluating the use of prescription sequence symmetry analysis as a pharmacovigilance tool: a scoping review. Res
Soc Adm Pharm. 2022;18:3079–93.
Takeuchi Y, Shinozaki T, Matsuyama Y. A comparison of estimators from self-controlled case series, case-crossover design, and
sequence symmetry analysis for pharmacoepidemiological studies. BMC Med Res Methodol. 2018;18:4.
Wang CH, Nguyen PA, Jack Li YC, Islam MM, Poly TN, Tran
QV, et al. Improved diagnosis-medication association mining to
reduce pseudo-associations. Comput Methods Programs Biomed.
2021;207:1066181.
Schotland P, Racz R, Jackson D, Levin R, Strauss DG, Burkhart
K. Target-adverse event profiles to augment pharmacovigilance: a
pilot study with six new molecular entities. CPT Pharmacometrics
Syst Pharmacol. 2018;7:809–17.
Schotland P, Racz R, Jackson DB, Soldatos TG, Levin R, Strauss
DG, et al. Target adverse event profiles for predictive safety in the
postmarket setting. Clin Pharmacol Ther. 2021;109:1232–43.
Lee S, Han J, Park RW, Kim GJ, Rim JH, Cho J, et al. Development of a controlled vocabulary-based adverse drug reaction
signal dictionary for multicenter electronic health record-based
pharmacovigilance. Drug Saf. 2019;42:657–70.
Koutkias V. From data silos to standardized, linked, and FAIR
data for pharmacovigilance: current advances and challenges with
observational healthcare data. Drug Saf. 2019;42:583–6.
Arfè A, Corrao G. The lag-time approach improved drug-outcome
association estimates in presence of protopathic bias. J Clin Epidemiol. 2016;78:101–7.
...
論文の公開元へ
